With multiple mid- and late-stage failures of its only clinical-stage compound, Corbus Pharmaceuticals is attempting to move forward with earlier-stage assets it in-licensed this summer. So the biopharma hired Takeda oncology leader Rachael Brake as chief scientific officer to lead those efforts.
Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ High potency anti-αvβ8 mAb licensed from University.
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Corbus Pharmaceuticals announced the expansion of its portfolio into immuno-oncology through licensing deals with the University of California San Francisco and Panorama Research Inc for two new monoclonal antibodies (mAbs).
Bolsonaro e Moro têm empate técnico em segundo turno, aponta pesquisa gazetadopovo.com.br - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gazetadopovo.com.br Daily Mail and Mail on Sunday newspapers.